We believe investors should 'Buy' AntriaBio, Inc. (OTCQB:ANTB) (post-split (OTCQB:ANTBD)), and our target is $5.25 per share. AntriaBio's lead product, AB101, is an ultra-long acting recombinant human insulin with a planned once-a-week dosing schedule that is intended for use in patients with both type 1 and type 2 diabetes. The compound is administered by subcutaneous injection and specifically formulated to release insulin slowly and uniformly over a sustained period of approximately one week without an adverse initial burst of insulin.
We believe that AB101 has tremendous potential as a basal insulin therapy given its once-weekly dosing schedule. With ultra long-acting insulin, AntriaBio is targeting a $10 billion global market. Once daily insulin products, comprised of Sanofi's Lantus
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|